A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective studySheri L. Spunt, Douglas S. Hawkins, Lynn Million et al.|The Lancet Oncology|2019Cited by 182
Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group D9602 StudyJohn C. Breneman, Douglas S. Hawkins, Jane L. Meza et al.|International Journal of Radiation Oncology*Biology*Physics|2011Cited by 78
Hematologic Abnormalities and Acute Myeloid Leukemia in Children and Adolescents Administered Intensified Chemotherapy for the Ewing Sarcoma Family of TumorsAlberto S. Pappo, Catherine A. Poquette, Neyssa Marina et al.|The American journal of pediatric hematology/oncology|2000Cited by 47
Results of treatment of fifty‐six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: A report from The Intergroup Rhabdomyosarcoma Study‐IV, 1991–1997R. Beverly Raney, William M. Crist, Julie A. Stoner et al.|Pediatric Blood & Cancer|2004Cited by 41
Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332.Sheri L. Spunt, Alberto S. Pappo, Lynn Million et al.|Journal of Clinical Oncology|2014Cited by 30